Titan Wealth CI Ltd Purchases Shares of 83,561 Edwards Lifesciences Corporation $EW

Titan Wealth CI Ltd acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, Holdings Channel.com reports. The fund acquired 83,561 shares of the medical research company’s stock, valued at approximately $7,123,000. Edwards Lifesciences accounts for about 2.7% of Titan Wealth CI Ltd’s portfolio, making the stock its 22nd largest position.

Several other large investors have also recently made changes to their positions in EW. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares in the last quarter. State Street Corp increased its stake in Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the last quarter. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the last quarter. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. Finally, Morgan Stanley raised its holdings in shares of Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after acquiring an additional 804,942 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 81,038 shares of company stock valued at $6,683,255 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $88.56 on Wednesday. The stock’s fifty day moving average is $83.03 and its 200 day moving average is $83.11. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $89.60. The firm has a market capitalization of $51.00 billion, a PE ratio of 47.11, a PEG ratio of 2.16 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on EW. Evercore reissued an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. TD Cowen restated a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.